596 Views
C1. Clinical trials (abstracts submitted to C1 should choose a secondary category that describes the subject matter of the trial)
Oral Abstract Submission
Bruno Francois, Physician
MD
CHU Dupuytren Limoges
Limoges, Limousin, France
Disclosure: ASTRAZENCA: Scientific Research Study Investigator
Miguel Sánchez Garcia, MD, PhD
Director
Hospital Clinico San Carlos
Madrid, Madrid, Spain
Disclosure: Nothing to disclose
Philippe Eggimann, MD
MD
University Hospital and Universits of Lausanne - Switzerland
Lausanne, Vaud, Switzerland
Disclosure: Nothing to disclose
Pierre-Francois Dequin, MD
Professor
Universite Francois Rabelais Hopital Bretonneau
Tours, Centre, France
Disclosure: Nothing to disclose
Pierre-François Laterre, MD
Prof
St Luc University Hospital, University of Louvain, Brussels, Belgium
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Disclosure: Nothing to disclose
Vincent Huberlant, MD
MD
Centre Hospitalier Jolimont-Lobbes
Jolimont-Lobbes, Hainaut, Belgium
Disclosure: Nothing to disclose
Lucia Viña Soria, MD
Physician
Hospital Universitario central de Asturias
Oviedo, Asturias, Spain
Disclosure: Nothing to disclose
Thierry Boulain, M.D.
Dr, Head of department
Centre Hospitalier Régional d'Orléans, Orléans, France
Orléans, Centre, France
Disclosure: Nothing to disclose
Cédric Bretonnière, MD, PhD
Dr
Institut du Thorax - CHU Nantes
Nantes, Pays de la Loire, France
Disclosure: Nothing to disclose
Jerome Pugin, MD
Professor
Hôpitaux Universitaire de Genève
Geneva, Geneve, Switzerland
Disclosure: Nothing to disclose
José Trenado Álvarez, MD, PhD
Director
Hospital Universitari Mutua Terrassa
Terrassa, Catalonia, Spain
Disclosure: Nothing to disclose
Ana Catalina Hernandez Padilla
MD
Centre Hospitalier Universitaire de Limoges, Limoges, France
Limoges, Limousin, France
Disclosure: Nothing to disclose
Frank Coenjaerts, PhD
Dr.
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands
Disclosure: Nothing to disclose
Omar Ali, Ph.D.
Associate Director, Clinical Development Scientist
AstraZeneca
Gaithersburg, MD
Disclosure: AstraZeneca: Employee, Shareholder
Kathryn Shoemaker, MS
Senior Principal Statistician
AstraZeneca
Gaithersburg, MD
Disclosure: AstraZeneca: Employee, Shareholder
Alexey Ruzin, PhD
Principal Scientist
AstraZeneca
Gaithersburg, MD
Disclosure: AstraZeneca: Employee, Shareholder
Innovative Medicines Initiative (IMI): Other Financial or Material Support, IMI grant # 115523, composed of European Union 7th Framework Programme FP7/2007-2013 and EFPIA in-kind contributions
Vadryn Pierre, PharmD
Senior Clinical Pharmacokineticist
Astrazeneca
Columbia, MD
Disclosure: Astrazeneca: Employee
Yuling Wu, PhD
Associate Director
Biopharma
Gaithersburg, MD
Disclosure: AstraZeneca: Employee
AstraZeneca: Employee
Susan Colbert, RN, BSN
Senior Clinical Program Manager
Gaithersburg, MD
Disclosure: Nothing to disclose
Michael McCarthy, MD
Product Development Team leader
MedImmune
Gaithersburg, MD
Disclosure: AstraZeneca: Employee
Filip Dubovsky, MD, MPH
Vice-President
AstraZeneca
Gaithersburg, MD
Disclosure: AstraZeneca: Employee, Shareholder
Background : Staphylococcus aureus (SA) pneumonia imposes significant morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, AT-neutralizing antibodies (AT NAbs), and safety of suvratoxumab (suvra) in MV ICU subjects in the placebo-controlled, randomized Phase 2 SAATELLITE study (NCT02296320; EudraCT 2014-001097-34).
Methods : Subjects with PCR-confirmed SA colonization of the lower respiratory tract were randomized to either a single intravenous infusion of 5000 mg suvra (n=96) or placebo (n=100) and followed for 190 days post dose. Efficacy endpoints were Endpoint Adjudication Committee-determined relative risk reduction (RRR) of SA pneumonia incidence in suvra vs. placebo recipients within 30 days post dose (primary endpoint, tested at 2-sided α=0.1), incidence of all-cause pneumonia, and all-cause pneumonia or death. Serum suvra PK and levels of AT NAbs were measured through 90 days post dose and analyzed for statistical correlation. Treatment-emergent adverse events (TEAEs) and serious AEs (SAEs) were assessed through 190 days post dose.
Results : Baseline characteristics were similar between groups. Suvra provided 31.9% RRR in incidence of SA pneumonia vs. placebo (17.7% vs 26%; P=0.166), 30% RRR (P=0.146) in incidence of all-cause pneumonia, and 23% RRR (P=0.164) in incidence of all-cause pneumonia or death. Suvra reduced mean hospital stay and ICU duration by 3.0 and 2.4 days, resp. vs. placebo. Mean serum±SD suvra level was 296±131 µg/ml at 30 days post dose. Serum AT NAb±SD levels reached 156.03±72.48 IU/mL at 2 days post dose, declining slowly to 33.74±16.04 IU/mL by 90 days post dose. AT NAbs correlated with PK (r2=0.7), thereby confirming functional activity of suvra over time. Proportion of subjects with TEAEs or SAEs were similar between groups: ≥1 TEAE (93.8% suvra; 93.0% placebo); ≥1 serious and/or ≥grade 3 severity SAE (66.7% suvra; 58.0% placebo).
Conclusion : A single intravenous dose of suvra produced a trend toward reduced incidence of SA pneumonia, health resource savings, sustained functional exposure in serum, and an acceptable safety profile. These results support continued development of suvra in MV ICU patients.